Navigation Links
Drug Reduces Inflammatory Arthritis Symptoms, Lesions
Date:2/12/2009

Ustekinumab effective for those who don't respond to current treatments, study finds

THURSDAY, Feb. 12 (HealthDay News) -- The drug ustekinumab shows promise against psoriatic arthritis (PA), according to a study that included patients from 24 sites in Europe and North America.

PA affects about 11 percent of patients with psoriasis, an autoimmune disease that affects the skin and joints. Some patients don't respond to current drug treatments for PA, so researchers are trying to find alternative therapies, according to background information in a news release about the study.

It's believed that interleukins 12 and 23 may play a role in PA. Interleukins are immune system-produced proteins that mediate inflammatory reactions in diseases such as psoriasis. Ustekinumab prevents interleukins 12 and 23 from binding to cell membranes.

In this study, patients were randomly assigned to receive either: ustekinumab (90 milligrams or 63 milligrams) every week for four weeks, followed by placebo at weeks 12 and 16 (76 patients -- Group 1); or placebo (weeks 0-3) and ustekinumab (63 milligrams) at weeks 12 and 16 (70 patients -- Group 2).

At week 12 of the trial, 42 percent of patients in Group 1 showed improvement, compared with 14 percent of those in Group 2. Of the 124 patients with psoriasis affecting 3 percent or more body surface area, 33 of 63 (52 percent) in Group 1 and three of 55 (5 percent) in Group 2 had a 75 percent or greater improvement in psoriasis area and severity index score at week 12 of the study.

"Our findings show that ustekinumab is efficacious and safe for treatment of active psoriatic arthritis. Our study is one of the first to implicate the role of interleukin 12/23 P40 cytokines in the pathophysiology of this disorder. Larger and longer term studies are needed to further characterize ustekinumab efficacy and safety for treatment of psoriatic arthritis," wrote Dr. Alice Gottlieb, of the dermatology department at Tufts Medical Center in Boston, and colleagues.

The study was published online and was expected to be in an upcoming print issue of The Lancet.

"The efficacy of ustekinumab for improving skin and joint involvement, which was maintained for several months, combined with good tolerability and a benign safety profile, make this agent an attractive option in psoriatic arthritis," Dr. Raquel S. Cuchacovich and Dr. Luis R. Espinoza, of LSU Health Sciences Center in New Orleans, wrote in an accompanying editorial.

More information

The National Psoriasis Foundation has more about psoriatric arthritis.



-- Robert Preidt



SOURCE: The Lancet, news release, Feb. 11, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. KV Pharmaceutical Company Reduces Workforce
2. Weight loss reduces incontinence in obese women, UCSF study shows
3. Weight Loss Reduces Incontinence In Obese Women, UCSF Study Shows
4. Study: Adding Vimpat significantly reduces partial-onset seizures in adults with epilepsy
5. Intensive Insulin Therapy Reduces Mortality in Sick Kids
6. New treatment reduces severity of asthma attacks in preschoolers
7. Abnormal Heart Function Reduces Exercise Capacity
8. Montreal Jewish General Hospital Improves Care and Reduces Costs With Motorolas Enterprise Mobility Solution
9. Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care
10. Telephone support after traffic accidents reduces problems and improves quality of life
11. Circumcision reduces the risk of HIV infection in heterosexual US men
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Reduces Inflammatory Arthritis Symptoms, Lesions
(Date:5/6/2016)... , ... May 06, 2016 , ... Canadian author Mark Black is a ... Life From the Heart" around the world … with the help of his publisher Strategic ... 24, Mark Black lay in a hospital bed waiting for a miracle: He needed a ...
(Date:5/6/2016)... ... May 06, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... he has found in the Bible about helping to stop cancer. Yisrayl says there are ... his hope that the health and science industries will pay close attention and take action. ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... David Konur, CEO of Cardiovascular Institute of the South announced today that Dr. ... a live case of an Intravascular Ultrasound Guided Coronary Atherectomy. , ...
(Date:5/5/2016)... ... May 05, 2016 , ... While the practice and profession ... the impact our aging population has on communities and resources. Aging Life Care plays ... and face age-related challenges. , Aging Life Care is a holistic, client-centered approach ...
(Date:5/5/2016)... ... May 05, 2016 , ... The U.S. Food and ... e-cigarette manufacturers to submit their products through an arduous federal approval process. The ... that entered the market since February 15, 2007. That would essentially ban 99 ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016 ... of Jerusalem announced today that it had signed ... BioTheryX, Inc. , developer of novel protein degradation and ... development and commercialization of drug candidates representing first-in-class therapy ... license were not disclosed. The novel technology ...
(Date:5/4/2016)... May 4, 2016 ... the  "Global Acute Myeloid Leukemia Market and ... their offering.       (Logo: ... Leukemia Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Myeloid Leukemia epidemiology, Acute ...
(Date:5/3/2016)... Research and Markets has announced ... Therapy Market Outlook 2020" report to their offering. ... ,Recombinant technology has improved significantly in past years due ... in coming years. Many cancer drugs have been developed ... are also expected to be developed with its help. ...
Breaking Medicine Technology: